Group items matching

in title, tags, annotations or url

Shares in GSK, Sanofi, Haleon and Pfizer began to recover on Friday (Aug 12) after the companies said that nothing material had changed regarding US litigation focused on heartburn drug Zantac. The companies' share prices had fallen sharply last week on investor concern about the litigation over potential cancer-causing impurities that prompted the drug's withdrawal from markets in 2019 and 2020. More than 2,000 Zantac-related legal cases have been filed in the United States, analysts say, with the first trial beginning this month. The prospect of impending Zantac litigation is not new. Among other disclosures, recently listed Haleon had highlighted the risk of such lawsuits in its prospectus. GSK, Sanofi, Pfizer and Haleon have lost a combined $39 billion from their market value over the past week in the absence of any other particular catalyst, according to Barclays analysts.

A member of the English Pharmacy Board and RPS Assembly, Sharon Isobel Tait Buckle (also known as Sibby) has been elected unopposed as the treasurer of the Royal Pharmaceutical Society (RPS). Sibby takes over the role from Andre Yeung, whose tenure ended in June 2022. Sibby was first elected to the English board in 2012 and is the first woman to hold the post since RPS became the professional leadership body in 2010. She is already part of the Finance and Investment Committee, where RPS budgets, pensions, assets, financial priorities and performance, reserves and investment policies are scrutinised and agreed. Commenting on her new role, Buckle said: "I want to build on the great contribution made by our previous Treasurer. Over the next two years of my tenure I will monitor and challenge our financial performance, our focus on Environmental, Social and Governance factors (ESG), investment strategy and performance and our financial governance.

The Pharmaceutical Services Negotiating Committee (PSNC) has notified that it is now mandatory to attend face-to-face training for both injection technique and basic life support training periodically for pharmacists and other vaccinators providing the annual flu vaccination service. "Community pharmacy contractors are required to demonstrate that all vaccinators, including pharmacists, providing the flu vaccination service in their pharmacy have the skills needed to do so," said PSNC. Prior to this change, pharmacists and other vaccinators needed to undertake a refresher face-to-face training for both injection technique and basic life support, including administration of adrenaline, every three years. Vaccinator needs to evidence competence PSNC said: "Contractors and vaccinators will now need to consider when it would be appropriate to attend refresher training or if ongoing competence of an individual vaccinator can be evidenced, without the need for face-to-face training. "An individual's continued competence may be influenced by their prior experience vaccinating patients, including the overall number of vaccines administered and the regularity with which they administer vaccines."

Ending the TB epidemic will require an accelerated, collaborative global effort from diverse scientific disciplines, Read this blog for latest national-strategic-plan-for-tuberculosis-elimination.

Ceuta Group has appointed Michael Yates as chief operating officer (COO). In his new role, he will focus on the exploration of future acquisitions to support the Group's growth plans and ensure it continues to provide innovative services and unlock new opportunities for its clients. Prior to joining Ceuta Group, Yates was associated with Procter & Gamble (P&G) for more than 25 years. His career started in the UK and progressed through senior commercial and managing director roles across Europe, Africa and Asia. During his time at P&G, Yates gained insight and experience in building brands in the UK and globally. He has broad category experience across food & drink as well as health, wellness and personal care, having worked with brands such as Pringles, Sunny Delight, Oral B, Vicks, Head & Shoulders and Pantene. With extensive international experience, Michael brings client-side knowledge and insight of successfully expanding brands and adapting business models for markets across the globe. His appointment bolsters Ceuta Group's leadership structure and will support the Group's growth plans and delivery of superior client service.

Pharmanovia, the lifecycle management company has signed a licence and supply agreement with Aquestive Therapeutics for its patented diazepam buccal film formulation across the EU, UK, Switzerland, and Norway, as well as countries in the Middle East and North Africa (MENA)- up to 48 markets in total. Aquestive Therapeutics has been granted tentative approval by the US Food and Drug Administration (FDA), for its diazepam buccal film for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. Pharmanovia will be responsible for seeking appropriate regulatory approval across EU and MENA. Pharmanovia CEO, James Burt commented: "Pharmanovia and Aquestive are aligned in our mission to find new and innovative ways to enhance and revitalise iconic medicines. We have extensive experience with diazepam through the Valium brand and, together with Aquestive's unique PharmFilm technology, we're intending to bring a novel alternative diazepam delivery option to caregivers and patients at a time of critical need."

The message of Diwali - a festival of new beginnings and the triumph of good over evil and light over darkness - seems to take on new layers of meaning every year. At the height of the Covid pandemic, it brought to mind the importance of togetherness, as we all struggled through lockdowns and missed the human contact that is so important to us all. In 2022, sadly, it feels like there's a lot of darkness in the world. Diwali is so full of hope for the future and we certainly need some of that that right now. In troubled times, both in the UK and across the globe, Diwali provides an opportunity to reflect and hope for better times ahead. In their own way, pharmacies bring light to the communities they serve - giving help and reassurance to many vulnerable people. As chair of the NPA it is truly a privilege to support pharmacy teams to deliver this vital work all year round. Diwali is a family feast - at the NPA we like to think of ourselves as the family of family-owned pharmacies.

The Pharmaceutical Services Negotiating Committee (PSNC) has appointed Sunil Kumar, an independent contractor from Darlington, as the Regional Representative for the North East and Cumbria region. "Kumar will represent all independent contractors in the region at the PSNC Committee until 31st March 2023, which is the end of the current term for all Regional Representatives," said PSNC. PSNC's North East and Cumbria region covers the areas of Community Pharmacy County Durham; Community Pharmacy Cumbria; Gateshead & South Tyneside LPC; North of Tyne LPC; Sunderland LPC and Tees LPC.

The Pharmaceutical Society NI (PSNI) has announced that Michaela McAleer will be replacing Trevor Patterson as Chief Executive of PSNI. After 15 years at the helm, Patterson announced his intention to retire. Jonathan Patton, Vice President of the Society said, "Joining the Society from the construction sector Trevor brought fresh thinking and vigour to the Society and quickly established his credibility with pharmacists, Council, stakeholders and fellow regulatory bodies." "Trevor has presided over tremendous change and development through his tenure with equal measures of professionalism and passion on creating safer protections for the public and ensuring pharmacists achieved world class standards in their profession. We are saddened to see him depart but on behalf of Council I wish him a long and healthy retirement and wish him well in the next chapter of life. We are indebted to him for his dedication to the Pharmaceutical Society NI." "Losing the constant and continuity of our 15 year serving Chief Executive ushers in a time of change and evolution for us as the Pharmacy Regulator. We are in the midst of a fast moving and changing environment as we implement continuous improvement.

The National Pharmacy Association (NPA) and BeWell are working together to help provide efficiencies and productivity that address the growing pressures within community pharmacy. BeWell's Pharmacy Management Platform provides robust solutions that include Patient Relationship Management, Omnichannel Communications and Engagement, Services and Bookings Management, access to patient records, NHS Login supported Patient Application, and repeat prescription capabilities for Pharmacy Website and Patient App that include integrations with Surgery Online Services. This single interoperable platform is also integrated with pharmacy PMRs, connecting back office and administrative functions with front-of-house digital patient experiences. In line with the NPA's vision, BeWell has taken a leading role in formulating a unique ecosystem of pharmacy partners uniting marketing agencies, PGD-based service providers, and delivery method partners - integrating their capabilities within the BeWell platform.

Pharmacy bodies and MPs discussed on support needed to unlock the "full potential" of community pharmacy at the All Pharmacy Party Group (APPG)'s general meeting held in Westminster on Tuesday (01 November). The attendees of the meeting were Janet Morrison OBE, Chief Executive of Pharmaceutical Services Negotiating Committee; Malcolm Harrison, Chief Executive of The Company Chemists' Association; Thorrun Govind, Chair of the Royal Pharmaceutical Society; Sanjeev Panesar, National Pharmacy Association Board Member, and Pharmacist Superintendent and Owner of the Pan Pharmacy Group; and Sandeep Dhami, Association of Independent Multiple Pharmacies member and superintendent at MW Phillips Chemist At the session, 18 parliamentarians were briefed on the myriad of ways pharmacies contribute to the health of the nation. The panel of experts also highlighted that pharmacists are 'running out of fuel' with the growing challenges such as flat funding, workforce shortages and the cost-of-living crisis impacting pharmacies' ability to deliver vital services.

A University College London team of researchers has developed an artificial intelligence (AI) programme that can identify minute brain anomalies that lead to epileptic seizures. The algorithm, used in the Multicentre Epilepsy Lesion Detection project (MELD) and which reports locations of abnormalities in cases of drug-resistant focal cortical dysplasia (FCD) - a major cause of epilepsy - was developed by a multinational team who used more than 1,000 patient MRI scans from 22 international epilepsy centres. Brain regions known as FCDs have evolved improperly and frequently lead to drug-resistant epilepsy. Surgery is usually used to treat it, however, finding the lesions on an MRI is a constant problem for doctors because MRI scans for FCDs can appear normal. The scientists employed about 300,000 places throughout the brain to quantify cortical properties from the MRI scans, such as how thick or folded the cortex/brain surface was.

Northern Ireland's chief pharmaceutical officer paid a visit to a community pharmacy in Belfast on Monday (November 7) - marking the end of this year's Ask Your Pharmacist week, an annual public awareness campaign launched by the National Pharmacy Association. Cathy Harrison interacted with patients and staff in the pharmacy before recording a video to promote NI's 'Pharmacy First' service in which she described community pharmacies as "one of the front doors to the health service" with over 500 outlets located across the country. "In our community pharmacies you can always rely on friendly staff, medicines expertise, and walk-in access to face-to-face advice," she said. First launched in Scotland, the NHS Pharmacy First service enables patients to have a consultation with a pharmacist for advice on minor ailments. Ms Harrison also drew attention to community pharmacy's role in cancer awareness and helping people to quit smoking, as well as managing patients with urinary tract infections, in addition to playing their part in delivering Covid-19 and flu vaccinations.

Bestway operates approximately 750 pharmacies nationwide in the UK under the Well brand. In April 2023, it completed its acquisition of Lexon, which operates 46 pharmacies in the UK under the Knights Pharmacy brand, and Asurex, a wholesale perfume supplier. On 26th May 2023, CMA announced the launch of its merger inquiry. A fast-track Phase 1 investigation found that the merger could lead to a significant lessening of competition between retail pharmacies in 12 local areas located in Liverpool and North East England. The merging businesses conceded that the deal raises competition concerns in these areas and have submitted proposals to sell pharmacies within these areas to restore the competition that would otherwise be lost as a result of the deal. Colin Raftery, CMA Senior Director of Mergers, said: "Pharmacies are essential public health services, and it's vital that the loss of competition brought about by a deal like this shouldn't leave people with reduced choice or worse services when they need medical support. The CMA will now carefully consider whether the remedy put forward by Bestway will address its concerns and ensure that customers in the affected areas continue to have access to good quality chemists.

The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June). The paper details how a financially sustainable VPAS can support widened medicines access to patients. VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. "The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme, data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the association.

A pharmacy group operating in London and the surrounding areas has said it's cliched a financial deal worth £4.25 million with a major global bank to bolster its mergers and acquisitions activity. Osbon Pharmacy Group said on Monday (19 June) that it would use the multi-million-pound funding package from HSBC UK to also invest in bringing accessible and comprehensive medical services closer to the doorstep of Londoners and people of South East England. The family-run business said the new money will open new position which will include opportunities for pharmacists, pharmacy assistants, pharmacy technicians, dispensers, accounts clerks and delivery drivers, taking the company's total headcount to 185. The group, which currently has 26 pharmacies across London and South East England, was established in 2005. The company offers a range of medicine and prescription services as well as offering customary help and advice. It switched to banking with HSBC UK last year as part of a £6.9M refinance package, which saw the business acquire nine pharmacies and takes the total funding provided by HSBC UK to date to £11.1m.

Glenmark, a multinational pharmaceutical company, has partnered with AI data-driven supply chain management platform 7bridges. Initially focusing on their European business, where they have operations in 15 markets, the supply chain and logistics function is a big focus area for this cost reduction. The partnership with 7bridges will allow Glenmark to baseline their supply chain data giving them visibility of data, cost and service performance across their network of logistics service providers. This exercise will identify areas where invoices from their logistics service providers are being incorrectly or overcharged. With automatic dispute raising, savings will be quickly achieved. The platform will then enable Glenmark to benchmark their data, so they can compare the performance and cost of their LSPs to the wider industry. With Glenmark's global vision to emerge as a leading integrated research-based global pharmaceutical company, this investment in their supply chain will be integral to achieving this. The next step in the partnership will be to run simulations to optimise road freight services and 3PL operations, with the aim to then roll out globally.

The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair. DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly. With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca. She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services. In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to prepare for the proposed spin out of the company from its parent, Novartis, expected later this year. She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing the sustainability of our industry so we can continue to play our vital part in the health of the nation." Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through her role on the BGMA board and leadership of a key strategic committee.

The Department of Health and Social Care (DHSC) has invited views of healthcare professionals and others to tackle the six major health conditions which drive-ill health and contribute to the burden of disease in England. The six major health conditions - cancer; cardiovascular diseases including stroke and diabetes; chronic respiratory diseases; dementia; mental ill-health and musculoskeletal disorders - affect millions of people in England with data showing that one in four suffer from two or more of these major long-term conditions. Recognising the pressure these conditions are putting on the NHS, the government is seeking views on a new strategy to tackle them that will focus not only on treatment but also on prevention. Government is particularly interested in hearing from those who suffer from, care for or provide treatment to people who suffer from multiple long-term conditions. This is to ensure the Major Conditions Strategy is one that will better prevent, diagnose, manage and treat these conditions. Contributions are also encouraged from those working in NHS bodies, local government, the voluntary and community sector, and wider industry, on how best to tackle suffering from one or more of these major conditions. Particularly, it is seeking perspectives on how government and the NHS can work better together with different organisations and sectors to improve the nation's health.

The General Pharmaceutical Council (GPhC) has proposed a 7.5 per cent increase in all fees for pharmacies, pharmacists, pharmacy technicians, and foundation trainees, including those for registration and renewal from April 2024. According to the GPhC's proposal the pharmacist renewal fee would increase by £19 from £257 to £276; the pharmacy technician renewal fee would increase by £9 from £121 to £130 and the pharmacy premises renewal fee would increase by £27 from £365 to £392 Any changes would be effective from April 2024, which means fees will remain at current levels for this financial year, giving registrants and applicants time to prepare for any increase in subsequent years. Fees have been frozen for the last two years (2022 and 2023) to help reduce pressure on both pharmacy professionals and pharmacy owners. Chief Executive, Duncan Rudkin, said: "In the last few years, we have been able to avoid raising many of these fees by improving our efficiency and by using our financial reserves to cover any gap between our income and our outgoings. While we are continuing to look for ways to make savings, we now have to consider increasing fees.